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Abstract
Background: Carcinoma of the thyroid gland is an uncommon cancer, but the most frequent malignancy of the
endocrine system. Most thyroid cancers are derived from the follicular cell. Follicular carcinoma (FTC) is considered
more malignant than papillary thyroid carcinoma (PTC), and anaplastic thyroid cancer (ATC) is one of the most lethal
human cancers. Opioid Growth Factor (OGF; chemical term - [Met5]-enkephalin) and its receptor, OGFr, form an
inhibitory axis regulating cell proliferation. Both the peptide and receptor have been detected in a wide variety of cancers,
and OGF is currently used clinically as a biotherapy for some non-thyroid neoplasias. This study addressed the question
of whether the OGF-OGFr axis is present and functional in human thyroid follicular cell - derived cancer.
Methods: Utilizing human ATC (KAT-18), PTC (KTC-1), and FTC (WRO 82-1) cell lines, immunohistochemistry was
employed to ascertain the presence and location of OGF and OGFr. The growth characteristics in the presence of OGF
or the opioid antagonist naltrexone (NTX), and the specificity of opioid peptides for proliferation of ATC, were
established in KAT-18 cells. Dependence on peptide and receptor were investigated using neutralization studies with
antibodies and siRNA experiments, respectively. The mechanism of peptide action on DNA synthesis and cell survival
was ascertained. The ubiquity of the OGF-OGFr axis in thyroid follicular cell-derived cancer was assessed in KTC-1
(PTC) and WRO 82-1 (FTC) tumor cells.
Results: OGF and OGFr were present in KAT-18 cells. Concentrations of 10-6 M OGF inhibited cell replication up to
30%, whereas NTX increased cell growth up to 35% relative to cultures treated with sterile water. OGF treatment
reduced cell number by as much as 38% in KAT-18 ATC in a dose-dependent and receptor-mediated manner. OGF
antibodies neutralized the inhibitory effects of OGF, and siRNA knockdown of OGFr negated growth inhibition by OGF.
Cell survival was not altered by OGF, but DNA synthesis as recorded by BrdU incorporation was depressed by 28% in
OGF-treated cultures compared to those exposed to sterile water. The OGF-OGFr axis was detected and functional in
PTC (KTC-1) and FTC (WRO 82-1) cell lines.
Conclusion: These data suggest that OGF and OGFr are present in follicular-derived thyroid cancers, and that OGF
serves in a tonically active inhibitory manner to maintain homeostasis of cell proliferation. These results may provide a
biotherapeutic strategy in the treatment of these cancers.
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Background
Thyroid cancer accounts for over 37,000 persons in the
U.S. annually, but only 1,600 deaths [1]. Five to 10% of
patients with thyroid cancer eventually will die of their
disease. It is one of the few malignancies that are more
common in females than males (M/F sex ratio, 0.36) [2].
While most thyroid cancers are differentiated and readily
treated with ionizing radiation and/or surgery [3,4], cell
type is an important determinant of prognosis in thyroid
cancer. Thyroid neoplasms arising from follicular cells
show a broad range of overlapping clinical and cytologic
features [5,6]. Papillary (PTC), follicular (FTC), and ana-
plastic (ATC) thyroid carcinomas arise from endoder-
mally derived follicular cells present in the thyroid gland.
FTC generally comprises about 15% of all diagnosed thy-
roid cancers and is usually a more aggressive form of can-
cer than the more common papillary type. Despite its
well-differentiated characteristics, FTC may be overtly
invasive. In fact, FTC may spread easily to other organs.
Life expectancy of affected patients is related to their age.
Two to 4% of all thyroid cancers are ATC. ATC generally
occurs in a setting of previous thyroid pathology (e.g., pre-
existing FTC or PTC). The overall 5-year survival rate for
ATC is reportedly less than 8%, and most patients do not
live longer than a few months after diagnosis. Death usu-
ally occurs as a result of local extension and airway com-
promise or complications from lung metastasis.
Treatment is palliative, with a combination of radio- and
chemotherapy and tracheostomy tube placement. Surgery
is reserved for early tumors without significant extension
or local invasion [7,8]. Despite preclinical studies explor-
ing new therapies targeted to molecular pathways [9-13],
more effective therapeutic approaches are needed.
The opioid growth factor (OGF), chemically termed
[Met5]-enkephalin, is an endogenous opioid peptide that
is an important regulator in the onset and progression of
a variety of human cancers [14-19]. OGF interacts with
the OGF receptor (OGFr) to delay the G1/S interface of the
cell cycle by modulating cyclin-dependent kinase inhibi-
tory (CKI) pathways [20-23]. Attenuation of the OGF-
OGFr axis in cancer cells through: i) disruption of OGF-
OGFr interfacing by continuous exposure to opioid antag-
onists (e.g., naltrexone, NTX) [14,17,19], ii) neutraliza-
tion of OGF by antibodies to the peptide [14,24], or iii) a
decrease in OGFr by antisense cDNA or siRNA for OGFr
[24,25], stimulates cell proliferation. An increase in OGF-
OGFr activity in cancer cells by i) addition of exogenous
OGF [14-19], ii) treatment with imidazoquinoline com-
pounds such as imiquimod and resiquimod [24], or iii)
transfection of sense cDNA for OGFr [26-29], depresses
cell proliferation.
Recently, OGF and OGFr have been detected by immuno-
histochemistry in surgical samples of non-medullary thy-
roid cancer including papillary, follicular, and anaplastic,
as well as thyroid tissue from patients with non-malignant
disease [30]. Moreover, receptor binding data in this
report showed that these specimens revealed specific and
saturable binding for the nuclear associated OGFr. These
results suggest that the OGF-OGFr axis is present in malig-
nant and non-malignant human thyroid tissue.
The present investigation explored the question of
whether the OGF-OGFr axis is present and functions in
thyroid follicular cell-derived cancer, including the most
deadly and untreatable form of thyroid cancer - ATC.
Using human ATC, PTC, and FTC cell lines, each previ-
ously verified by single nucleotide polymorphism array
analysis, the OGF-OGFr axis was identified and character-
ized functionally. In addition, the specificity of both OGF
and OGFr in regulating cell proliferation was determined
and mechanisms of peptide action elucidated.
Methods
Cell lines and cell proliferation assays
The ATC cell line, KAT-18, was generously provided by Dr.
K.B. Ain, The University of Kentucky, Lexington, KY) and
the FTC cell line, WRO 82-1, was established by Dr. G.
Juillard (University of California at Los Angeles, CA). The
poorly differentiated papillary thyroid carcinoma cell
line, KTC-1 [31], was a generous gift of Dr. James A. Fagin
(Memorial Sloan Kettering Cancer Center, New York,
NY). The KAT-18 cells were grown in phenol-red free
RPMI 1640 media (GIBCO/Invitrogen, Carlsbad, CA),
and the WRO 82-1 and KTC-1 cells were grown in stand-
ard RPMI 1640 media supplemented with 1% non-essen-
tial amino acids. All media were supplemented with 10%
fetal calf serum, 2 mM L-glutamine, 1.2% sodium bicar-
bonate, and antibiotics (5,000 Units/ml penicillin, 5 mg/
ml streptomycin, 10 mg/ml neomycin). The cell cultures
were maintained in a humidified atmosphere of 5% CO2
at 37°C. All cell lines were free of Mycoplasma and con-
firmed by single nucleotide polymorphism array analysis
to be unique follicular cell-derived thyroid cancer cell
lines [32].
Cells were seeded at equivalent amounts into 6- or 24-
well plates (Falcon) and counted 24 h later (time 0) to
determine plating efficiency. OGF or other compounds
were added daily; an equivalent volume of sterile water (3
l) was added to control wells (Co). Media and com-
pounds were replaced daily. Cells were harvested by
trypsinization with 0.25% trypsin/0.53 mM EDTA, centri-
fuged, and counted with a hemacytometer. Cell viability
was determined by trypan blue staining. At least two aliq-
uots per well, and 2-4 wells/treatment, were counted for
each experiment. Two to five experiments were conducted
for each measure performed.BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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DNA synthesis, apoptosis and necrosis
The effects of OGF on DNA synthesis (BrdU incorpora-
tion), apoptosis (TUNEL), and necrosis (trypan blue)
were evaluated. To examine DNA synthesis, KAT-18 cells
were seeded onto 22 mm diameter coverglasses placed in
6-well plates (3 × 103 cells/coverglass), and treated with
compounds for 72 h; media and drugs were replaced
daily. Three h prior to fixing cells, 30 M BrdU (Sigma
Chemicals, Indianapolis, IN) was added to cultures. Cells
were rinsed, fixed in 10% neutral buffered formalin for 10
min, and stained with antibodies to BrdU (anti-BrdU-
BOD, Roche/Invitrogen). At least 1000 cells/treatment
using at least 2 coverglasses/treatment were counted, and
the number of positive cells recorded. Labeling indexes
were calculated as the number of positive stained cells
divided by total cells.
To detect late-stage apoptosis, TUNEL assays (Trevigen,
Gaithersburg, MD) were performed on KAT-18 cells
seeded on coverglasses in 6-well plates and treated with
OGF or sterile water beginning 24 h later; drugs and
media were replaced daily. Cells were harvested after 72 h
of drug treatment, and TUNEL assays conducted accord-
ing to manufacturer's recommendations.
Necrosis was recorded as the number of positive trypan
blue cells in any cell growth assay.
Immunohistochemistry
To examine for the presence of OGF and OGFr, log-phase
KAT-18, KTC-1, and WRO 82-1 cells were plated onto 22
mm round coverglasses. After 72 h in culture, cells were
fixed and permeabilized in 95% ethanol and acetone at -
20°C, and processed according to previously published
procedures [14]. Cells were incubated with ammonium
sulfate purified anti- [Met5]-enkephalin IgG (CO172) [33]
or anti-OGFr-IgG (BO344) [33,34] antibodies diluted
1:250 in Sorenson's phosphate buffer containing 1% nor-
mal goat serum and 0.1% Triton X-100 for 18 h at 4°C,
washed and incubated with goat anti-rabbit IgG (1:1000)
conjugated to rhodamine prior to viewing with fluores-
cence microscopy. Coverglasses containing cells that were
incubated with secondary antibody only served as con-
trols.
OGFr binding assays
Binding assays for OGFr were performed with procedures
described earlier [26,27]. In brief, log phase KAT-18 cells
were harvested, and the nuclear fraction isolated through
sucrose gradient centrifugation. Binding saturation iso-
therms were determined by specific binding of custom-
synthesized [3H]- [Met5]-enkephalin (Perkin Elmer-New
England Nuclear; 52.7 Ci/mmol). Independent assays
were performed 2 to 4 times in duplicate.
Specificity of endogenous OGF
To determine the specificity of endogenous OGF, log-
phase KAT-18 cells were exposed to a polyclonal antibody
to OGF (1:200; CO172) [33] or to pre-immune rabbit
serum (1:200) as a control. Serum and media were
changed daily, and cells counted after 72 h. Cell viability
was determined by trypan blue staining. At least two aliq-
uots per well, and 2-6 wells/treatment, were counted.
siRNA knockdown of OGFr: Northern analyses and semi-
quantitative immunohistochemistry
The OGFr-targeted siRNAs (antisense:5'-uagaaacucagguu-
uggcg-3'; sense: 5'-cgccaaaccugaguuucua-3') were
designed and obtained as ready-annealed, purified duplex
probes from Ambion (Austin, TX) [25]. For transfection, 5
× 104 KAT-18 cells per well were seeded in 6-well plates
containing 1 ml of serum-containing media without anti-
biotics. In each well, 20 nM OGFr-siRNA or control siRNA
solutions in serum-free media were added. Cells were
incubated for 4 h at 37°C prior to the addition of OGF or
NTX (10-6 M). Cultures were incubated an additional 20
h, and then 1 ml fresh complete media either lacking or
containing OGF or NTX was added. At 72 h cells were col-
lected for computing growth. Two independent experi-
ments were conducted. The scrambled siRNAs were
purchased from Ambion.
Some cultures were transfected with siRNAs and then har-
vested 72 h later for Northern analysis. Total RNA was
extracted using the Paris Kit (Ambion), separated on an
agarose gel, and mRNA transferred to nylon membrane
(Immobilon, Bio-Rad Laboratories, Hercules, CA). Mem-
branes were probed with 32P-dCTP- OGFr cDNA. To deter-
mine equal loading, blots were stripped and reprobed
with radiolabeled GAPDH and optical density of each
band was determined by densitometry and analyzed by
QuickOne (Bio-Rad Laboratories). Each value was nor-
malized to GAPDH from the same blot.
KAT-18 cells were seeded onto coverglasses, transiently
transfected with OGFr-siRNA, and 72 h later stained with
polyclonal antibodies to OGFr in order to detect the level
of protein knockdown. OGFr protein levels were assessed
by semi-quantitative immunocytochemistry whereby
images were taken at the same exposure time with special
care not to photobleach samples. The mean intensity of
staining was determined for approximately 50 cells/
group.
Chemicals
The following compounds were obtained from the indi-
cated sources: [Met5]-enkephalin, [Leu5]-enkephalin, [D-
Pen2,5]-enkephalin (DPDPE), [D-Ala2, MePhe4, Glycol5]-
enkephalin (DAMGO), -endorphin, naltrexone (NTX),
naloxone, dynorphin A1-8 (Dynorphin), morphine sul-BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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fate, endomorphin 1 (Endo 1), endomorphin 2 (Endo 2),
Sigma (St. Louis, MO); U69,583, Upjohn Diagnostics
(Kalamazoo, MI).
Statistical analyses
All calculations were performed with GraphPad Prism
software. Cell numbers and intensity measurements were
analyzed using two-tailed t-tests or analysis of variance
with subsequent comparisons made using Newman-Keuls
tests.
Results
OGF and OGFr are present in anaplastic thyroid cells
Antibodies to OGF and to OGFr were used with immuno-
histochemistry to determine the presence and location of
this growth-related peptide and its receptor in cultures of
KAT-18 (Fig. 1). Immunoreactive OGF and OGFr were
localized to the cytoplasm with speckling noted in the
nucleus. No staining was recorded in control specimens
processed with secondary antibody only.
Receptor binding analyses of KAT-18 revealed specific and
saturable binding, with a one-site model of binding. The
binding capacity (Bmax) was 9.3 ± 0.6 fmol/mg protein
and binding affinity (Kd) was 3.5 ± 0.6 nM.
OGF depresses growth of anaplastic thyroid cells in a dose-
dependent, receptor mediated, and reversible manner
The effects of OGF on KAT-18 cells were evaluated in
dose-response studies (Fig. 2A). At 72 h, dosages of 10-4,
10-5, and 10-6 M OGF reduced cell number by 38%, 13%,
and 14%, respectively, from control levels. Exposure to
10-7 M OGF had no significant effect on cell number in
comparison to control values. Using a dose of 10-6 M
OGF, cultures were reduced in cell number by 13% to
30% from control cultures (Fig. 2B) over a 96 h period of
time.
In order to determine whether the inhibitory effect of
OGF was mediated by an opioid receptor, KAT-18 cells
were grown in the presence of OGF and the short-acting
opioid receptor antagonist naloxone (10-6 M; Nal) (Fig.
2C). Cell number was reduced by 20% in cultures treated
with 10-6 M OGF compared to control levels, whereas cul-
tures receiving both OGF and naloxone or naloxone alone
had no change in cell number.
To address the question of whether the effects of OGF on
cell number persisted after removal of the drug, a study
was performed to determine if the inhibitory effects of
OGF could be reversed (Fig. 2D). At 72 h after exposure to
10-6 M OGF, wherein a reduction of 22% in cell number
was recorded compared to control levels, cell cultures
grown in media replenished without OGF were reduced
by 6% and 8%, respectively, from control cultures at 96
and 120 h. In contrast, cultures maintained on OGF were
depressed 16% and 28% at 96 and 120 h, respectively,
from cells subjected to sterile water. At 120 h, cells
released from OGF exposure were 21% greater in number
than those continuing to receive OGF; this difference was
statistically significant at p < 0.01. Calculation of the
increase in number of cells/h for log-phase growth
(between 96 h and 120 h after seeding) indicated that the
controls grew at a rate of 7,083 cells/h in contrast to a rate
of 6,375 cells/h for the group exposed to OGF and subse-
quently incubated in compound-free media. Cultures
continuing to be maintained on OGF (i.e., exposure to
OGF for 120 h), increased at a rate of 4,083 cells/h during
this period.
The endogenous opioid specific for growth inhibition of 
anaplastic thyroid cells is OGF
Although OGF inhibits the growth of ATC cells, a variety
of other endogenous and exogenous opioids and opioid
antagonists were tested for their ability to alter cell
number (Fig. 3A). Log phase cultures of KAT-18 cells were
exposed to 10-6 M concentrations, a dosage of OGF shown
to significantly reduce growth from controls at 72 h of
exposure. Compounds were chosen as those that were
specific agonists to classical opioid receptors (, ,  ):
DAMGO, morphine, endomorphin 1, endomorphin 2,
DPDPE, dynorphin A1-8, U69683, and -endorphin.
Only OGF altered cell proliferation significantly; OGF
decreased cell number by 33% from controls (Fig. 3A).
The effect of the general opioid antagonist NTX on the
growth of human ATC cells showed that this drug
The presence and distribution of OGF and OGFr in human  anaplastic thyroid cancer cells Figure 1
The presence and distribution of OGF and OGFr in 
human anaplastic thyroid cancer cells. Photomicro-
graphs of log-phase KAT-18 cells visualized with differential 
interference or stained with antibodies to [Met5]-enkephalin 
(OGF) or OGFr. Immunoreactivity was associated with the 
cytoplasm and a speckling of stain was noted in cell nuclei; no 
staining was observed with secondary antibodies only (inset). 
Scale bar = 10 m.BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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increased cell number by 35% from control values after 72
h in culture (Fig. 3A).
The specificity of OGF action was further investigated by
adding polyclonal antibodies to OGF to determine the
effects of neutralization of endogenous OGF on cell
number (Fig. 3B). Cultures were treated with 10-6 M OGF,
OGF antibody CO172, or IgG. Cultures exposed to the
OGF antibody had 16% more cells than control cultures;
cultures treated with sterile water and those receiving IgG
had a similar number of cells.
Silencing of OGFr in human anaplastic thyroid cells 
attenuates the inhibitory action of endogenous and 
exogenous OGF
The requirement of the OGF receptor for OGF action on
cell proliferation was examined at the molecular level
using siRNA technology. Transfection of KAT-18 cells with
OGFr siRNA effectively knocked down OGFr activity (Fig.
4). Northern blot analyses revealed that transfected KAT-
18 cells had less than 25% OGFr relative to cells treated
with vehicle only (Fig. 4A); cells exposed to scrambled
siRNA were comparable to those receiving vehicle only.
OGF inhibits growth of human anaplastic thyroid cancer cells in a dose-dependent, receptor-mediated, and reversible manner Figure 2
OGF inhibits growth of human anaplastic thyroid cancer cells in a dose-dependent, receptor-mediated, and 
reversible manner. (A) Growth of KAT-18 cells subjected to various concentrations of opioid growth factor (OGF) of ster-
ile water (Co) for 72 h. (B) Growth of KAT-18 cells treated with OGF (10-6 M) or an equivalent volume of sterile water (Co) 
over a 96-h period of time. (C) Opioid receptor mediation of the growth inhibitory effects of OGF in KAT-18 cells. Cell cul-
tures were subjected to OGF (10-6 M), the opioid antagonist naloxone (Nal; 10-6 M), OGF and Nal, or sterile water (Co) for 72 
h. (D) Reversibility of the growth inhibitory effects on KAT-18 cells treated with 10-6 M OGF or sterile water (Co). At 72 h, 
one-half of the culture plates continued to receive OGF for an additional 48 h, and one-half of the plates were treated with 
sterile water for 48 h. Control cultures received sterile water throughout the 120 h. For all experiments, data represent mean 
SE for at least 2 aliquots/well from 2 wells/group. Two to five experiments were conducted for each measure. Significantly dif-
ferent from respective controls at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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Immunocytochemical staining of cells transfected with
siRNA-OGFr was assessed semi-quantitatively and
revealed a 47% decrease in OGFr protein expression rela-
tive to both untransfected cells and those transfected with
scrambled siRNA (Fig. 4B). Silencing of OGFr activity
using siRNA technology resulted in functional changes as
indicated by cell number. KAT-18 cells transfected with
OGFr siRNA had approximately 70% more cells that cul-
tures exposed to vehicle only, as well as those transfected
with scrambled siRNA (Fig. 4C). Addition of exogenous
OGF had no effect on cells transfected with OGFr siRNA,
but cell number was reduced by 30% in both untrans-
fected cultures and those transfected with scrambled siR-
NAs. KAT-18 cells transfected with OGFr siRNA and
treated with OGF or sterile water did not differ in cell
number from each other, and all differed significantly
from wildtype cultures and those transfected with scram-
bled siRNAs.
NTX is a general opioid receptor antagonist that upregu-
lates cell number. To inquire as to whether NTX is
dependent on OGFr, cells treated with OGFr siRNA were
exposed to 10-6 M NTX. Untreated and scrambled siRNA
cultures exposed to NTX increased in cell number by 32%
in comparison to wildtype cells receiving vehicle. NTX
added to cultures receiving OGFr siRNA increased by 70%
in contrast to wildtype cells, and these cultures treated
with OGFr siRNA and exposed to NTX did not differ from
cells receiving OGFr siRNA plus vehicle.
OGF alters DNA synthesis but not apoptosis or necrosis
To examine the mechanism by which OGF reduces
human thyroid cancer cells in vitro, DNA synthesis of KAT-
18 cultures exposed to OGF, NTX, or sterile water was
measured (Fig. 5). The proportion of BrdU labeled cells in
cultures exposed to OGF was 28% less than that in cul-
tures receiving sterile water, while NTX increased DNA
synthesis by 25% relative to controls after 72 h of drug
exposure.
No differences in the number of apoptotic or necrotic cells
were noted between groups receiving sterile water, OGF,
or NTX (data not shown). In fact, relative to positive con-
trol samples for apoptosis, apoptosis (and necrosis) in
cultures treated with OGF, NTX, or saline was negligible.
The OGF-OGFr axis is present and functions in both 
papillary and follicular thyroid cancer cell lines
OGF and OGFr were detected in both KTC-1 (PTC) (Fig.
6A) and WRO 82-1 (FTC) (Fig. 7A) cell lines. After 72 h of
treatment with OGF (10-6 M) KTC-1 and WRO 82-1 cells
were reduced by 31% and 17% from respective control
levels (Figs. 6B, 7B). Exposure of KTC-1 and WRO 82-1
cells for 72 h to 10-6 M concentrations of NTX increased
cell number in both cell lines by 30% (Figs. 6B, 7B).
Discussion
A previous study in our laboratory has demonstrated the
presence of OGF and OGFr in human PTC, FTC, and ATC
surgical specimens [30]. A critical question arising from
this earlier investigation is whether opioids are present
and function in thyroid follicular cell - derived cancers.
Using a human ATC cell line, KAT-18, in a tissue culture
model, and confirming the presence of OGF and OGFr in
these human cells under in vitro conditions, we report for
the first time that opioids do indeed function in these
deadly neoplasias, subserving as modulators of cell prolif-
eration. The data reveal that at least one opioid, OGF,
OGF is the specific opioid peptide involved in the growth  inhibition of human anaplastic thyroid cancer cells Figure 3
OGF is the specific opioid peptide involved in the 
growth inhibition of human anaplastic thyroid can-
cer cells. (A) The effects of various endogenous and exog-
enous opioids (10-6 M) or sterile water (Co) on KAT-18 
cell number. (B) Cells were treated with an antibody spe-
cific for OGF (CO172), pre-immune serum (IgG), exoge-
nous OGF (10-6 M), or sterile water (Co). Cell number was 
measured at 72 h. Data for both experiments represent 
mean SE for at least 2 aliquots/well from 2 wells/group. 
Three experiments were conducted for each measure. Sig-
nificantly different from respective controls at p < 0.01 (**) 
or p < 0.001 (***).BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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exerted a dose-dependent inhibitory action on these ATC
cells as measured by changes in cell number. The growth
repression recorded was rapid, being observed within 24
h after initiating drug exposure, and continuing in the
presence of drug for up to 120 h. The effect of OGF was
mediated by opioid receptors, because an opioid antago-
Figure 4 
OGFr is required for OGF's inhibitory action on growth. (A) Northern blot analysis demonstrating the specificity of the OGFr
siRNA in KAT-18 cells. Log phase cells were transfected for 24 h with either scrambled siRNA or OGFr siRNA. Quantitative densitometry
(percent of OGFr/GAPDH ratio) represent mean ± SEM for 2 blots from independent experiments. Significantly different from non-trans-
fected cultures at p < 0.01 (**). (B) Immunocytochemical detection of OGFr demonstrating the knockdown of receptor protein. Photomi-
crographs of cultures transfected with OGFr siRNA, scrambled siRNA, or untransfected and stained with OGFr antibodies. Data (mean
gray value) represent mean ± SEM for fluorescence measurements of at least 50 cells. Significantly different from non-transfected cells
and those transfected with scrambled siRNA at p < 0.001 (***). (C) Growth of KAT-18 cultures transfected with OGFr siRNA or scram-
bled siRNA for 24 h and treated with either OGF (10-6 M), NTX (10-6 M), or an equivalent volume of sterile water for an additional 48 h;
compounds and media were changed daily. Values represent mean ± SE cell counts for 2 aliquots/well and 2 wells/treatment from three
experiments. Significantly different at p < 0.001 (***) from cultures that were not transfected as well as cells that were transfected with
scrambled siRNA.BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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nist of short duration and low potency, naloxone, blocked
the depression in cell acquisition but by itself did not have
any influence on cell replication. Moreover, the conse-
quences of OGF on repressing cell proliferation were
reversible when OGF-exposed cells were transferred from
OGF-containing media to fresh media without com-
pound, suggesting that this peptide acted in a cytostatic
rather than toxic manner. Examination of the ubiquity of
the OGF-OGFr axis in other types of follicular cell-derived
thyroid cancers revealed that both the peptide and recep-
tor were present, and that this biological system func-
tioned as a growth-inhibitory pathway. These data suggest
that the OGF-OGFr axis is present and a determinant of
thyroid follicular cell-derived cancers in tissue culture,
extending similar observations using surgical prepara-
tions [30]. Further research is needed to characterize this
system on other human PTC, FTC, and ATC cancer cell
lines, and to determine if the OGF-OGFr axis can modu-
late the growth of xenografts with these neoplasias.
Given that OGF is an endogenous opioid peptide, and
that this peptide was provided to the cells exogenously in
these initial experiments, we raised the question of
whether endogenous OGF itself is involved with regulat-
ing cell proliferation of thyroid follicular cell-derived can-
cers. In the first set of studies, we treated ATC cells with the
long acting and extremely potent general opioid antago-
nist, NTX. We reasoned that if endogenous opioids such
as OGF repressed cell proliferation, then blockade of opi-
oid peptides from opioid receptors should increase the
number of cells above control levels, especially if OGF was
continuously secreted and active in its regulatory role.
Indeed, administration of NTX increased cell number in
these cultures compared to cultures treated with either
vehicle or OGF. These data indicate that OGF is tonically
active in maintaining a homeostatic equilibrium of prolif-
eration of thyroid follicular cell-derived cancers. In a sec-
ond series of experiments, the assessment of a variety of
synthetic and natural neuropeptides related to opioid
receptors (particularly , , and ) were tested for their
ability to influence cell proliferation. Not one of these lig-
ands that recognized classical opioid receptors had an
effect on the proliferative properties of human ATC cells.
In a third series of experiments related to the question of
opioid specificity, cultures were exposed to an antibody to
OGF in order to examine whether this antibody could
neutralize OGF action. In fact, treatment with this anti-
body to OGF resulted in cell proliferation that was ele-
vated from control levels, thereby speaking to the
specificity of the endogenous opioid involved with repres-
DNA synthesis is a mechanism of OGF inhibition Figure 5
DNA synthesis is a mechanism of OGF inhibition. 
Human KAT-18 anaplastic thyroid cancer cells were treated 
with 10-6 M OGF or NTX, or an equivalent volume of sterile 
water (Co). Data represent the percent BrdU positive cells 
(mean ± SE). Significantly different from controls at p < 0.01 
(**).
The presence and distribution of OGF and OGFr in human  papillary thyroid cancer cells Figure 6
The presence and distribution of OGF and OGFr in 
human papillary thyroid cancer cells. (A) Photomicro-
graphs of log-phase KTC-1 cells visualized with differential 
interference (DIC) or stained with antibodies to [Met5]-
enkephalin (OGF) or OGFr. Immunoreactivity was associated 
with the cytoplasm and a speckling of stain was noted in cell 
nuclei; no staining was detected with secondary antibodies 
only (inset). Scale bar = 10 m. (B) KTC-1 cells were treated 
for 72 h with 10-6 M OGF or NTX, or sterile water (Co). Val-
ues represent mean ± SE for cells counted from 2 wells/treat-
ment group from three experiments. Significantly different 
from controls at p < 0.05 (*) or p < 0.001 (***).BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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sion of cell replication, as well as affirming and extending
the results of experiments with NTX showing that OGF
activity in regulating cell number is tonically active. In
addition, because OGF is known to be produced and
secreted by a variety of cancer and non-cancer cells [17],
our findings suggest that this peptide acts in an autocrine
and presumably paracrine manner in thyroid follicular
cell-derived cancer cells.
An extensive literature shows that OGF interacts with
OGFr to regulate cell the proliferation of human and ani-
mal cells, normal and cancer [14,15,17-29], implying that
the effect on control of cell number by endogenous OGF,
as well as exogenously administered peptide, is mediated
by this receptor. OGFr has been detected in ATC, FTC, and
PTC by immunohistochemistry, and specific and satura-
ble binding of OGF to OGFr was quantitated [30]. How-
ever, OGF is [Met5]-enkephalin and this opioid peptide is
known to bind to classical opioid receptors such as , ,
and  as well [23]. In order to examine the specificity of
OGF for OGFr with respect to regulation of cell prolifera-
tion, the effect of silencing OGFr using siRNA technology
was undertaken. KAT-18 (ATC) cells treated with OGFr
siRNA were observed to have an increase in cell number,
suggesting that attenuating OGFr compromised endog-
enously produced OGF. Moreover, exogenously adminis-
tered OGF which is known to depress cell number in log
phase cultures did not have any effect when the cells were
transfected with OGFr siRNA. In fact, there were a greater
number of cells in cultures treated with OGFr siRNA and
exposed to OGF than in cultures given vehicle or scram-
bled siRNA. An interesting observation in these studies is
that although the use of NTX, a general opioid receptor
blocking agent, increased cell number, knockdown of
OGFr by OGFr siRNA was over twice as effective. These
results are consistent with earlier findings using immuno-
electron microscopy showing that there is still some OGF-
OGFr activity even with treatment of NTX [35], indicating
"leakiness" with NTX blockade. That NTX is not the most
specific blocker of OGF-OGFr interaction is understanda-
ble because the OGF receptor has nucleotide and protein
sequences that are not in keeping with classical opioid
receptors [23]. Thus, NTX appears to have recognition of
OGFr, but does not provide a full blockade of OGF-OGFr
interfacing. All of these data support OGFr as the receptor
mediating OGF action. Taken together with knowledge
that OGF is the peptide involved with modulating cell
number of human thyroid follicular cell-derived cancer
cells, it is clear that proliferation of these carcinoma cells
is dependent on the OGF-OGFr axis.
A decrease in cell number as seen by treatment with OGF
could be due to a decrease in cell survival because of pro-
grammed cell death, necrosis, and/or a reduction in DNA
synthesis and subsequent cell replication. Our data show
that neither apoptosis nor necrosis are involved with OGF
activity in ATC cells, a result consistent with a previous
publication documenting a similar finding in a variety of
cancer cells growing in tissue culture [36]. However, DNA
synthesis measured over a 3-h period in ATC cells treated
with OGF was diminished from control levels by 28,
whereas blockade of OGF-OGFr interaction by NTX ele-
vated DNA synthesis by 25%. Consistent with previous
studies on head and neck cancers [14,20], these data indi-
cate that the mechanism of OGF involves regulation of
cell proliferation. Cheng et al. [21,22] have found that
OGF regulates the p16 pathway in human squamous cell
carcinoma and the p21 pathway in human pancreatic
neoplasia, suggesting that cyclin-dependent inhibitory
kinase (CKI) pathways are a target of OGF. Further studies
with human thyroid follicular cell-derived cancers are
warranted to see if one or both of these CKIs play a role in
OGF's regulatory activity of cell proliferation.
The presence and distribution of OGF and OGFr in human  follicular thyroid cancer cells Figure 7
The presence and distribution of OGF and OGFr in 
human follicular thyroid cancer cells. (A) Photomicro-
graphs of log-phase WRO 82-1 cells visualized with differen-
tial interference (DIC) or stained with antibodies to [Met5]-
enkephalin (OGF) or OGFr. Immunoreactivity was associ-
ated with the cytoplasm and a speckling of stain was noted in 
cell nuclei; no staining was recorded with secondary antibod-
ies only (inset). Scale bar = 10 m. (B) WRO 82-1 cells were 
treated for 48 h with 10-6 M OGF or NTX, or sterile water 
(Co). Values represent means ± SE for cells counted from 2 
wells/treatment group from three experiments. Significantly 
different from controls at p < 0.05 (*) or p < 0.001 (***).BMC Cancer 2009, 9:369 http://www.biomedcentral.com/1471-2407/9/369
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A critical question that needs to be addressed in future
studies is whether OGF has efficacy in modulating the
incidence and progression of human ATC, PTC, and FTC
in vivo. Preclinical experiments are needed to establish
whether this agent can alter the course of these lethal neo-
plasias. If successful, then the role of OGF in the etiology
and pathogenesis of these cancers will be an exciting ave-
nue to pursue and studies using OGF as an antitumor
agent in the clinic are warranted.
Conclusion
These data demonstrate that the OGF-OGFr axis is present
in follicular-derived thyroid cancers, and that OGF is a
tonically active inhibitory peptide that serves in a recep-
tor-mediated manner to repress proliferation of these thy-
roid cancer cells. These results support further
consideration on the use of OGF as a biotherapeutic strat-
egy in the treatment of follicular-derived thyroid cancers.
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